Table 1:

Patient demographics and clinical and biologic lesion characterization

Age (yr)	Sex	Overall Survival (mo)	Location	LM	ASCL1	CKB	Germline Mutation
0.15	F	0.5^{^a}	Posterior fossa	0	Negative	5.05
0.32	F	17.0	Posterior fossa	0	Positive	6.31	Yes
0.39	M	8.2^{^b}	Posterior fossa	1	Positive
0.64	M	7.0	Parietal lobe	0	Negative	5.10
0.67	M	0.5^{^a}	Posterior fossa	1	Positive
0.68	M	5.1	Intraventricular	0	ND
0.92	F	0.5^{^a}	Posterior fossa	1	Positive		Yes
0.95	M	71.9^{^b}	Posterior fossa	0	ND
1.09	M	13.0	Posterior fossa	0	Negative	5.31
1.14	M	7.0	Temporal lobe	0	Positive	6.05	Yes
1.15	M	59.0	Posterior fossa	0	Negative	6.31
1.42	F	9.0	Posterior fossa	1	ND
1.54	M	32.0	Temporal lobe	0	Positive	6.53	Yes
1.55	M	63.2^{^b}	Posterior fossa	0	Negative
1.73	M	13.0	Pineal	0	Positive
1.84	F	18.0	Frontotemporal	0	Negative	5.21
1.96	F	NA	Temporal lobe	1	ND
2.86	M	18.0	Frontotemporal	1	Positive	6.61
7.43	F	40.0	Frontotemporal	0	Positive	6.42
13.72	M	40.0	Intraventricular	0	Positive	5.71

Note:—NA indicates patient lost to follow up; LM, leptomeningeal disease present (1) versus absent (0) at presentation; ND, not determined.
↵a Patients who died from surgical/other complications with no MR imaging or clinical evidence of progressive tumor.
↵b Patients who were still alive at the time of the completion of this study.